Cue Biopharma, Inc. Common Stock, also called Cue Biopharma, is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Read More Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA. The listed name for CUE is Cue Biopharma, Inc. Common Stock.